XML 108 R94.htm IDEA: XBRL DOCUMENT
v3.23.2

Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) € in Millions | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2023 EUR (€) segment | Jun. 30, 2022 EUR (€) | Dec. 31, 2022 EUR (€) segment
Disclosure of geographical areas [line items] |  |  |
Net sales | € 20,187 | € 19,790 | € 42,997
Number of operating segments | segment | 2 |  | 3
Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | € 17,467 | 17,147 | € 37,812
Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 8,691 | 7,642 |
Biopharma | Dupixent |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 4,878 | 3,577 |
Biopharma | Aubagio |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 635 | 1,017 |
Biopharma | Cerezyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 377 | 367 |
Biopharma | Myozyme/Lumizyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 436 | 487 |
Biopharma | Fabrazyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 496 | 458 |
Biopharma | Jevtana |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 176 | 203 |
Biopharma | Alprolix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 260 | 237 |
Biopharma | Eloctate |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 248 | 291 |
Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 6,386 | 7,307 |
Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,182 | 3,205 |
Biopharma | Lovenox |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 607 | 714 |
Biopharma | Toujeo |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 580 | 541 |
Biopharma | Plavix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 476 | 508 |
Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,924 | 3,786 |
Biopharma | Lantus |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 800 | 1,271 |
Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,910 | 2,270 |
Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 280 | 316 |
Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,390 | 2,198 |
Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,154 | 1,202 |
Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 162 | 181 |
Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,720 | 2,643 | 5,185
Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 446 | 434 |
Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 559 | 582 |
Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 814 | 726 |
Europe |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5,034 | 4,767 | 9,999
Europe | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 4,194 | 3,986 |
Europe | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,621 | 1,535 |
Europe | Biopharma | Dupixent |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 587 | 450 |
Europe | Biopharma | Aubagio |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 249 | 269 |
Europe | Biopharma | Cerezyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 120 | 126 |
Europe | Biopharma | Myozyme/Lumizyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 181 | 206 |
Europe | Biopharma | Fabrazyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 122 | 116 |
Europe | Biopharma | Jevtana |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 8 | 19 |
Europe | Biopharma | Alprolix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 0 | 0 |
Europe | Biopharma | Eloctate |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 0 | 0 |
Europe | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,003 | 2,130 |
Europe | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,011 | 978 |
Europe | Biopharma | Lovenox |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 329 | 353 |
Europe | Biopharma | Toujeo |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 221 | 211 |
Europe | Biopharma | Plavix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 48 | 52 |
Europe | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 728 | 858 |
Europe | Biopharma | Lantus |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 191 | 223 |
Europe | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 497 | 593 |
Europe | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 264 | 294 |
Europe | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 570 | 321 |
Europe | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 148 | 161 |
Europe | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 37 | 37 |
Europe | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 840 | 781 |
Europe | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 49 | 37 |
Europe | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 254 | 261 |
Europe | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 285 | 252 |
United States |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7,988 | 7,562 | € 18,275
United States | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7,366 | 6,917 |
United States | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5,622 | 4,829 |
United States | Biopharma | Dupixent |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,682 | 2,653 |
United States | Biopharma | Aubagio |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 348 | 689 |
United States | Biopharma | Cerezyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 94 | 94 |
United States | Biopharma | Myozyme/Lumizyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 135 | 163 |
United States | Biopharma | Fabrazyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 251 | 221 |
United States | Biopharma | Jevtana |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 128 | 142 |
United States | Biopharma | Alprolix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 215 | 198 |
United States | Biopharma | Eloctate |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 183 | 232 |
United States | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,087 | 1,410 |
United States | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 762 | 773 |
United States | Biopharma | Lovenox |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5 | 7 |
United States | Biopharma | Toujeo |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 118 | 128 |
United States | Biopharma | Plavix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 4 | 5 |
United States | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 322 | 624 |
United States | Biopharma | Lantus |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 180 | 425 |
United States | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 139 | 196 |
United States | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3 | 13 |
United States | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 657 | 678 |
United States | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 200 | 224 |
United States | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 19 | 12 |
United States | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 622 | 645 |
United States | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 246 | 249 |
United States | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 89 | 103 |
United States | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 69 | 62 |
Other countries |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7,165 | 7,461 |
Other countries | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5,907 | 6,244 |
Other countries | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,448 | 1,278 |
Other countries | Biopharma | Dupixent |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 609 | 474 |
Other countries | Biopharma | Aubagio |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 38 | 59 |
Other countries | Biopharma | Cerezyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 163 | 147 |
Other countries | Biopharma | Myozyme/Lumizyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 120 | 118 |
Other countries | Biopharma | Fabrazyme |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 123 | 121 |
Other countries | Biopharma | Jevtana |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 40 | 42 |
Other countries | Biopharma | Alprolix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 45 | 39 |
Other countries | Biopharma | Eloctate |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 65 | 59 |
Other countries | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,296 | 3,767 |
Other countries | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,409 | 1,454 |
Other countries | Biopharma | Lovenox |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 273 | 354 |
Other countries | Biopharma | Toujeo |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 241 | 202 |
Other countries | Biopharma | Plavix |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 424 | 451 |
Other countries | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,874 | 2,304 |
Other countries | Biopharma | Lantus |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 429 | 623 |
Other countries | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,274 | 1,481 |
Other countries | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 13 | 9 |
Other countries | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,163 | 1,199 |
Other countries | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 806 | 817 |
Other countries | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 106 | 132 |
Other countries | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,258 | 1,217 |
Other countries | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 151 | 148 |
Other countries | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 216 | 218 |
Other countries | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | € 460 | € 412 |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of operating segments. + References No definition available. + Details
Name: | sny_NumberOfOperatingSegments
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DupixentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AubagioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MyozymeLumizymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_JevtanaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AlprolixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_GeneralMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PlavixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LantusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_OtherNonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AllergyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PainCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DigestiveWellnessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |